Progestin-Only Contraceptive Slynd Approved
June 6, 2019 – The U.S. FDA has approved Slynd™ (drospirenone), manufactured by Exeltis USA, for use by females of reproductive potential to prevent pregnancy. The drug is the first progestin-only pill (POP) for pregnancy prevention that offers a 24/4 dosing regimen and a 24-hour missed pill window.
While there are other POP products on the market, they require daily administration of an active pill. They also do not have a window of 24 hours in which to take a missed pill without compromising the effectiveness of contraception.
Slynd still offers effective contraception if a missed dose is taken within 24 hours. Its 24/4 recommended dosing regimen calls for taking one active 4mg pill daily for 24 days, then taking one inactive pill daily for four days. According to the manufacturer, this schedule can offer an improved bleeding profile.
Progestin-only contraception provides an alternative for females who cannot or do not wish to use estrogen-containing products due to certain medical conditions, sensitivity, or potential side effects. Unlike contraceptives that contain both estrogen and progestin, Slynd does not have a black box warning. However, females who have conditions that predispose them to hyperkalemia should not use the product.
Although pricing plans have not been announced, Exeltis expects to launch Slynd in early fall 2019.